Back to Agenda
Real-World Response: Harnessing Electronic Health Records to Develop Robust Clinical Endpoints in Solid Tumors
Session Chair(s)
Michael W. Lu, PharmD
Platform Strategy Leader, RWD, Personalized Healthcare Oncology, Genentech, A Member of the Roche Group, United States
RECIST-based response is an established endpoint in clinical trials, but how do you assess response in routine patient care? This session presents efforts to develop a real-world response endpoint and its utility in clinical development.
Learning Objective : Describe the utility of measuring treatment response in clinical trials and challenges of accessing it in routine clinical care; Discuss methods, data elements, and rigor needed to evaluate this endpoint and future implications for clinical development.
Speaker(s)
Ariel Bourla, MD, PhD
Medical Director, Flatiron Health, United States
Real-World Response: Harnessing Electronic Health Records to Develop Robust Clinical Endpoints in Solid Tumors
Michael W. Lu, PharmD
Platform Strategy Leader, RWD, Personalized Healthcare Oncology, Genentech, A Member of the Roche Group, United States
Application of Real-World Response in Prospective Studies
Gregory Riely, MD, PhD
Vice Chair, Clinical Research, Department of Medicine, Memorial Sloan Kettering Cancer Center, United States
Exploring Real-World Response and Progression Free Survival in the AACR GENIE Biopharma Collaborative
Have an account?